DARA BioSciences, Inc. (NASDAQ: DARA) shares closed up nearly 100% on Wednesday despite no significant news from the company. The stock traded in between 1.10 - 2.38 on about 15.3 million shares traded.
DARA BioSciences, Inc., a development stage biopharmaceutical company, develops and commercializes oncology treatment and supportive care pharmaceutical products in the United States. It offers Soltamox for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups.
Get more information on DARA BioSciences, Inc. and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/DARA
TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.
FormFactor Inc. (NASDAQ: FORM) shares closed up 16.34% on Wednesday with nearly 3 million shares traded after the company issued optimistic guidance for the second quarter. FormFactor increased its second quarter revenue forecast to between $65 million and $69 million from between $62 million and $66 million which came in above the Capital IQ Consensus Estimates of $63.5 million in revenue for the quarter. The company also increased its margin guidance to 34% to 37% from 31% to 34%.
FormFactor, Inc. designs, develops, manufactures, sells, and supports semiconductor wafer probe card products and solutions worldwide. Its wafer probe cards are used in the front end of the semiconductor manufacturing process to perform sort and test on the semiconductor die, or chips, on a semiconductor wafer.
Get more information on FormFactor Inc. and free access to the in depth equity report at” www.TrendingWallStreet.com/stockquote/FORM
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.